Supplementary material for Van den Bergh L, et al. Reliability of sentinel node procedure for lymph node staging in prostate cancer patients at high risk for lymph node involvement. Acta Oncol 2015;54:896–902.

Supplementary Table I. Overview of the 37 N+ patients and associated initial PSA, Gleason score, pT-stage, number of affected and resected nodes, details on LN regions per patient and performance of the SN procedure.

Patient ID	Initial PSA (ng/ml)	Primary tumor Gleason score	pT-stage	Number of LN removed	Number N+		Number of N+ regions (total number of regions)	Number of N+ regions containing a SN	Correctly staged with SN procedure	All N+ resected with SN dissection
					SN	Non SN				
2	8.24	4 + 3	2c	42	1	0	1 (9)	1	Y	Y
6	9.8	4 + 3	3a	26	0	4	3 (9)	0	N	N
7	8.13	4 + 3	2c	25	0	1	1 (9)	0	N	N
8	6.25	4 + 5	3b	32	0	9	4 (9)	1	N	N
9	9.7	4 + 4	2c	13	1	0	1 (10)	1	Y	Y
13	21.75	4 + 4	3a	18	3	3	4 (9)	2	Y	N
14	10.6	4 + 4	3b	20	1	1	2 (9)	1	Y	N
17	8.67	4 + 3	2c	20	1	0	1 (9)	1	Y	Y
18	8.23	4 + 5	3a	19	2	1	3 (9)	2	Y	N
19	14.9	4 + 3	3a	21	1	1	2 (10)	1	Y	N
20	6.8	4 + 5	3b	24	2	0	2 (9)	2	Y	Y
21	12.3	3 + 4	2c	16	0	1	1 (9)	0	N	N
22	12.4	4 + 5	3b	23	1	3	4 (9)	1	Y	N
24	10.6	4 + 4	3b	17	2	0	2 (9)	2	Y	Y
25	13.3	4 + 5	3b	23	1	3	3 (9)	1	Y	N
29	5.8	4 + 3	3b	19	1	1	2 (8)	1	Y	N
30	14.4	4 + 3	3a	19	3	0	3 (9)	3	Y	Y
35	13.5	4 + 4	3b	10	1	0	1 (9)	1	Y	Y
38	16	4 + 5	3b	22	1	3	4 (9)	2	Y	N
41	15.47	4 + 5	3b	19	0	2	2 (9)	0	N	N
45	11	4 + 4	3a	15	1	0	1 (9)	1	Y	Y
46	14.97	3 + 4	2c	27	0	1	1 (9)	0	N	N
48	20	4 + 4	3b	10	2	2	3 (8)	2	Y	N
50	8.8	3 + 4	3a	21	4	0	3 (9)	3	Y	Y
52	8	4 + 5	3b	17	0	1	1 (9)	0	N	N
55	7.8	4 + 5	3a	15	1	0	1 (9)	1	Y	Y
56	13.8	4 + 4	3b	29	3	2	4 (10)	2	Y	N
58	9	4 + 3	3b	13	1	0	1 (9)	1	Y	Y
60	8.8	4 + 4	3b	13	1	0	1 (8)	1	Y	Y
61	11.7	4 + 4	3a	39	2	0	1 (10)	1	Y	Y
62	11.4	4 + 5	3b	21	3	5	5 (9)	2	Y	N
65	6.01	5 + 5	3b	24	4	6	7 (9)	4	Y	N
67	5.04	4 + 3	3b	34	0	3	2 (10)	0	N	N
68	7.4	4 + 4	2c	49	2	0	2 (9)	2	Y	Y
70	12.8	4 + 4	3a	28	0	1	1 (9)	1	N	N
71	12.5	5 + 4	3b	42	3	0	2 (9)	2	Y	Y
74	25	4 + 5	4	34	1	2	3 (9)	1	Y	N
All	Median 10.6	-	-	Median 21	50	56	85 (335)	47	28/37 Y	15/37 Y

ID, identifier; LN , lymph node; N, no; N+, affected lymph node(s); PSA, prostate-specific antigen; SN, sentinel node; Y, yes.

Supplementary Table II. Overview of all N+ patients with residual LN metastases after SN dissection and the minimal LND template needed in order to remove these affected nodes.

Patient ID	Number non-SN N+	Dimension of non-SN N+			Template minimally needed in addition to SN LND in order to
		ITC	Micro	Macro	
6	4	0	3	1	seLND
7	1	0	1	0	oLND
8	9	1	5	3	seLND
13	3	0	1	2	seLND
14	1	0	0	1	oLND
18	1	0	0	1	eLND
19	1	0	1	0	lLND
21	1	0	1	0	eLND
22	3	1	0	2	eLND
25	3	1	1	1	lLND
29	1	0	0	1	lLND
38	3	0	0	3	eLND
41	2	0	0	2	eLND
46	1	0	0	1	eLND
48	2	0	2	0	eLND
52	1	0	1	0	oLND
56	2	2	0	0	seLND
62	5	0	2	3	seLND
65	6	0	2	4	seLND
67	3	0	3	0	lLND
70	1	1	0	0	lLND
74	2	0	1	1	lLND
All	56	6	24	26	-

eLND, extended lymph node dissection; ITC, isolated tumor cells; lLND, limited lymph node dissection; LND, lymph node dissection; macro, macrometastasis; micro, micrometastasis; N+, affected lymph node(s); oLND, obturator lymph node dissection; seLND, superextended lymph node dissection; SN, sentinel node; ID, identifier.